531599 Share Price Performance
Recent 531599 News & Updates
No updates
FDC Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 07, 2025
- Earnings per share (EPS)
- 16.39
- Gross Margin
- 65.07%
- Net Profit Margin
- 12.66%
- Debt/Equity Ratio
- 0.005%
FDC Limited Competitors
About 531599
- Founded
- 1936
- Employees
- 6659
- CEO
- WebsiteView website
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names. The company was founded in 1936 and is headquartered in Mumbai, India.
Indian Market Performance
- 7 Days: -1.6%
- 3 Months: 3.8%
- 1 Year: -6.5%
- Year to Date: -2.0%
Over the last 7 days, the market has dropped 1.6%, driven by a decline of 2.1% in the Financials sector. The market has dropped 6.5% in the last year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading